Dispensing Pattern of Generic and Brand-Name Drugs in Children

Ambulatory Pediatrics

Volumn 8, Issue 3, 2008, Pages 189-194

  Chen, Alex Y ^a   Wu, Susan ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

generic drugs; medical expenditure panel survey; prescription drugs

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BRAND NAME DRUG; BRONCHODILATING AGENT; CENTRAL STIMULANT AGENT; CEPHALOSPORIN; DERMATOLOGICAL AGENT; DRUG; GENERIC DRUG; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G;

ADOLESCENT; AGE; ARTICLE; ASIAN AMERICAN; CAUCASIAN; CHILD; CHILD CARE; DEMOGRAPHY; DRUG COST; DRUG USE; DRUG UTILIZATION; FEMALE; GENDER BIAS; HEALTH STATUS; HUMAN; INCOME; INFANT; INSURANCE; MALE; PRESCRIPTION; RACE DIFFERENCE; SOCIAL ASPECT; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUGS, GENERIC; FEMALE; HEALTH CARE SURVEYS; HUMANS; INFANT; MALE; PATENTS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 44049096020     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ambp.2007.12.008     Document Type: Article

References (39)

1. Smith C., Cowan C., Heffler S., Catlin A., and the National Health Accounts Team. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff (Millwood) 25 (2006) 186-196
2. Borger C., Smith S., Truffer C., et al. Health spending projections through 2015: changes on the horizon. Health Aff (Millwood) 25 (2006) w61-w73
3. Dubois R.W., Chawla A.J., Neslusan C.A., Smith M.W., and Wade S. Explaining drug spending trends: does perception match reality?. Health Aff (Millwood) 19 (2000) 231-239
4. Schondelmeyer S.W., and Thomas III J. Trends in retail prescription expenditures. Health Aff (Millwood) 9 (1990) 131-145
5. Foote S.M., and Etheredge L. Increasing use of new prescription drugs: a case study. Health Aff (Millwood) 19 (2000) 165-170
6. Kaiser Family Foundation. Prescription Drug Trends. Report 3057-05 (2006), Henry J. Kaiser Family Foundation, Menlo Park, Calif
7. Morden N.E., and Sullivan S.D. States' control of prescription drug spending: a heterogeneous approach. Health Aff (Millwood) 24 (2005) 1032-1038
8. Crowley J.S., Ashner D., and Elam L. State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Report 7381 (2005), Henry J. Kaiser Foundation, Washington, DC
9. Lichtenberg F.R. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. Am J Manag Care 11 (2005) SP7-SP13
10. Wang J., Zuckerman I.H., Miller N.A., Shaya F.T., Noel J.M., and Mullins C.D. Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res 42 (2007) 1499-1519
11. Krobot K.J., Miller W.C., Kaufman J.S., Chrisensen D.B., Preisser J.S., and Ibrahim M.A. The disparity in access to new medication by type of health insurance: lessons from Germany. Med Care 42 (2004) 487-491
12. Lichtenberg F.R. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood) 20 (2001) 241-225
13. Reuveni H., Sheizaf B., Elhayany A., et al. The effect of drug co-payment policy on the purchase of prescription drugs for children with infections in the community. Health Policy 62 (2002) 1-13
14. Huskamp H.A., Deverka P.A., Epstein A.M., et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry 62 (2005) 435-441
15. Kennedy J., Coyne J., and Sclar D. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther 26 (2004) 607-614
16. Cunningham P.J. Medicaid cost containment and access to prescription drugs. Health Aff (Millwood) 24 (2005) 780-789
17. Saha A., Grabowski H., Birnbaum H., Greenberg P., and Bizan O. Generic competition in the US pharmaceutical industry. Int J Econ Bus (2006) 1315-1338
18. Blier P. Generic medications: another variable in the treatment of illnesses. J Psychopharmacol 21 (2007) 459-460
19. Alloway R.R., Isaacs R., Lake K., et al. Report of the American Society of Transplantation Conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 3 (2003) 1211-1215
20. Taber D.J., Baillie G.M., Ashcraft E.E., et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?. Transplantation 80 (2005) 1633-1635
21. Burroughs V.J., Maxey R.W., and Levy R.A. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 94 (2002) 1-26
22. Andersen R.M. Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behavior 36 (1995) 1-10
23. Cohen JW, Monheit AC, Beauregard KM, et al. The medical expenditure panel survey: a national health information resource. Inquiry. 1996-1997;33:373-389.
24. MEPS HC-070: 2002 full year consolidated data file. December 2004. Available at: http://www.meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h70/h70do c.pdf. Accessed January 14, 2007.
25. Cerner Multum Inc. Available at: http://www.multum.com/Lexicon.htm. Accessed January 14, 2008.
26. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, Calif: University of California Press; 1967;1:221-223.
27. Fischer M.A., and Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 38 (2003) 1051-1063
28. Haas J.S., Phillips K.A., Gerstenberger E.P., and Seger A.C. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med 142 (2005) 891-897
29. Hong S.-H., and Shepherd M.D. Outpatient prescription drug use by children enrolled in five drug benefit plans. Clin Ther 18 (1996) 528-545
30. Straand J., Rokstad K., and Heggedal U. Drug prescribing for children in general practice. A report from the More and Romsdal Prescription Study. Acta Paediatr 87 (1998) 218-224
31. Roe C.M., McNAmara A.M., and Motheral B.R. Gender- and age-related prescription drug use patterns. Ann Pharmacother 36 (2002) 30-39
32. Kuno E., and Rothbard A.B. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 159 (2002) 567-572
33. Tamayo-Sarver J.H., Hinze S.W., Cydulka R.K., and Baker D.W. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 93 (2003) 2067-2073
34. Finkelstein J.A., Lozano P., Farber H.J., Miroshnik I., and Lieu T.A. Underuse of controller medications among medicaid-insured children with asthma. Arch Pediatr Adolesc Med 156 (2002) 562-567
35. Zito J.M., Safer D.J., Zuckerman I.H., Gardner J.F., and Soeken K. Effect of medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr Serv 56 (2005) 157-163
36. Mamdani M.M., Tu K., Austin P.C., and Alter D.A. Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 36 (2002) 804-808
37. Taira D.A., Iwane K.A., and Chung R.S. Prescription drugs: elderly enrollee reports of financial access, receipt of free samples, and discussion of generic equivalents related to type of coverage. Am J Manag Care 9 (2003) 305-312
38. Wosinska M., and Huckman R.S. Generic dispensing and substitution in mail and retail pharmacies. Health Aff (Millwood) (2004) (Suppl Web Exclusives):W4409-W4416
39. Mott D.A., and Cline R.R. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 40 (2002) 662-674